Self-Administered Autoimmune Injectables

Friday, November 16, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 15, 2018 /PRNewswire/ -- The advantages of administering immunotherapeutic injectables subcutaneously is now

well accepted and has been more-or-less institutionalized in the drug life cycle development process for non-oncology indications. Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled
into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. The migration to patient self-care presents several areas of concern. By making the patient the single point of failure for dosing adherence and successful drug delivery, devices and protocols must be developed and tested to a new, higher standard. New generation drug injection devices are increasingly being created to address patient adherence issues by making the delivery of injectable drugs less complicated and intimidating. Read the full report: https://www.reportlinker.com/p05621766 Self-Administered Autoimmune Injectables – What You Will Learn• What approved drugs indicated for autoimmune conditions are marketed for self-administration, what is the as-supplied packaging, and who markets them?• What are the major factors driving the migration of infusible drugs for treating autoimmunity to formulations that can be packaged and administered subcutaneously?• What is the size of the market for self-administered autoimmune injectable drugs today, who are the market share leaders, and what will the market share be in 2022?• How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?• What are the essential design factors, technologies and market development issues for devices that can deliver injectable autoimmune drugs subcutaneously?• What are the significant economic, technology, and regulatory factors affecting the market for immunotherapeutic drugs?Read the full report: https://www.reportlinker.com/p05621766 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/self-administered-autoimmune-injectables-300751525.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store